The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.6, 2005-01, pp. : 607-618

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab may be cost effective in severe, treatment-resistant RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 480, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Infliximab may be cost effective in severe, treatment-resistant RA

Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of TNF-α-blocking agents in the treatment of rheumatoid arthritis

By Merkesdal Sonja Ruof Jörg Mittendorf Thomas Zeidler Henning

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 9, 2004-09 ,pp. : 1881-1886

Informa Healthcare

Access to resources Recommend Favorite

Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis

By Mikuls T.R.

Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. : 23-32

Adis International

Access to resources Recommend Favorite

A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis

By Nuijten M.J.C.

PharmacoEconomics, Vol. 19, Iss. 10, 2001-01 ,pp. : 1051-1064

Adis International

Access to resources Recommend Favorite